MOTCO’s BioMarin Pharmaceuticals BMRN Stock Holding History

MOTCO’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28	Closed	-$2.43K	–	852
2023 Q2	$2.43K	Buy	+28	New	+$2.63K	﹤0.01%	631
2022 Q2	–	Sell	-52	Closed	-$4K	–	567
2022 Q1	$4K	Hold	52	–	–	﹤0.01%	543
2021 Q4	$5K	Hold	52	–	–	﹤0.01%	516
2021 Q3	$4K	Hold	52	–	–	﹤0.01%	554
2021 Q2	$4K	Hold	52	–	–	﹤0.01%	559
2021 Q1	$4K	Hold	52	–	–	﹤0.01%	523
2020 Q4	$5K	Hold	52	–	–	﹤0.01%	583
2020 Q3	$4K	Buy	+52	New	+$5.26K	﹤0.01%	529
2019 Q4	–	Sell	-46	Closed	-$3K	–	532
2019 Q3	$3K	Sell	46 -215	-82%	-$16.6K	﹤0.01%	473
2019 Q2	$22K	Buy	+261	New	+$22.3K	﹤0.01%	472
2018 Q4	–	Sell	-112	Closed	-$11K	–	565
2018 Q3	$11K	Buy	+112	New	+$11.2K	﹤0.01%	471

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MOTCO's BMRN Position: Q3 2023 in Review

MOTCO sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 28 shares — an estimated $2.43K sold.

MOTCO first reported a position in BMRN in Q3 2018 and held it in 11 quarters. The position peaked at $22K in Q2 2019. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

MOTCO reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
MOTCO sold 28 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $2.43K.
MOTCO first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 11 quarters.
MOTCO's BioMarin Pharmaceuticals position peaked at $22K in Q2 2019.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on MOTCO's 13F filing for Q3 2023, filed 7 Nov 2023.